Peripheral neuropathy in transgenic diabetic mice - Restoration of C-fiber function with human recombinant nerve growth factor

被引:48
|
作者
Elias, KA
Cronin, MJ
Stewart, TA
Carlsen, RC
机构
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Univ Calif Davis, Sch Med, Dept Human Physiol, Davis, CA USA
关键词
D O I
10.2337/diabetes.47.10.1637
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mice (Ins.D(d)1) with hypoinsulinemic diabetes were created by increased expression of syngeneic major histocompatibility complex (MHC) class I protein in pancreatic beta-cells. The diabetic state was characterized in these mice by high glucose concentrations and islet pathology. To determine whether a neuropathy would develop, motor and sensory conduction velocities (CV) were determined in the sciatic nerves of 2-, 4-, and 7-month-old control and diabetic littermate male mice. Recording bipolar electrodes were placed in the plantar muscles of the hind foot of anesthetized (ketamine/xylazine) mice. Bipolar stimulating electrodes mere positioned near the sciatic nerve at the sciatic notch or near the tibial nerve at the ankle. Motor CV from cu-motor fibers and sensory CV from proprioceptive Aa nerves were measured and expressed as meters per second (m/s). Group data are reported as mean +/- SE and compared by analysis of variance. The CVs from nondiabetic mice (controls) were not different across the three ages and averaged 41.3 +/- 1.7 m/s for motor and 38.7 +/- 1.7 m/s for sensory. The motor CVs from diabetic mice at 2 and 4 months were similar to controls. Sensory CVs were unchanged at 2 months but were lower at 4 months (18.9 +/- 2.4 m/s). Both sensory (23.9 +/- 2.1 m/s) and motor (18.9 +/- 1.8 m/s) CVs were significantly reduced at 7 months, which is indicative of a polyneuropathy. NGF has well-known trophic effects on sympathetic and small sensory neurons. To determine whether NGF could influence this neuropathy, 6-month-old control and diabetic mice were divided into the following groups: 1) control + vehicle, 2) diabetic + vehicle, and 3) diabetic + NGF (1 mg/kg, 3 x week, s.c.). After 1 month of treatment, motor and sensory CVs were determined. In some mice, the branches of the sciatic nerve were exposed and in situ recordings from the sural nerve were performed to determine compound C-fiber CV, integral, and amplitude. Sensory CV, determined via Hoffmann's reflex (H-reflex) (A-fiber), was decreased in diabetic compared with control animals as expected (P < 0.05), and NGF did not alter this parameter. Continuing diabetes reduced the amplitude (0.9 +/- 0.2 vs. 3.2 +/- 0.7 mV x 10(-2); P < 0.05) and integral (6.9 +/- 1.9 mV/ms vs. 18.8 +/- 4,4 mV/ms; P < 0.05) of the C-fiber response versus control, suggesting fiber loss. NGF treatment normalized C-fiber amplitude (2.9 +/- 0.8 mV x 10(-2)) and integral(21.2 +/- 6.5 mV/ms) in animals with established diabetes, with no effect on blood glucose. The C-fiber CV was similar in all groups, indicating that the animals had some normally conducting small fiber sensory nerves. These studies characterized a motor and sensory polyneuropathy in transgenic diabetic mice and are the first to demonstrate directly that NGF treatment can protect or restore abnormal sensory C-fiber function.
引用
收藏
页码:1637 / 1642
页数:6
相关论文
共 50 条
  • [31] Aldose reductase pathway inhibition improved vascular and C-fiber functions, allowing for pressure-induced vasodilation restoration during severe diabetic neuropathy
    Demiot, C
    Tartas, M
    Fromy, B
    Abraham, P
    Saumet, JL
    Sigaudo-Roussel, D
    DIABETES, 2006, 55 (05) : 1478 - 1483
  • [32] Nerve growth factor release from the urothelium increases via activation of bladder C-fiber in rats with cerebral infarction
    Yokokawa, Ryusei
    Akino, Hironobu
    Ito, Hideaki
    Zha, Xinmin
    Yokoyama, Osamu
    NEUROUROLOGY AND URODYNAMICS, 2017, 36 (06) : 1448 - 1455
  • [33] OVEREXPRESSION OF NERVE GROWTH-FACTOR IN EPIDERMIS OF TRANSGENIC MICE CAUSES HYPERTROPHY OF THE PERIPHERAL NERVOUS-SYSTEM
    ALBERS, KM
    WRIGHT, DE
    DAVIS, BM
    JOURNAL OF NEUROSCIENCE, 1994, 14 (03): : 1422 - 1432
  • [34] RECOMBINANT HUMAN NERVE GROWTH-FACTOR PROTECTS AGAINST CISPLATIN PROPRIOCEPTIVE DEFECT IN MICE
    CRONIN, M
    SORIANO, R
    LYON, R
    FASEB JOURNAL, 1992, 6 (05): : A1916 - A1916
  • [35] LOW CONTENTS OF NERVE GROWTH-FACTOR IN SERUM AND SUBMAXILLARY-GLAND OF DIABETIC MICE - A POSSIBLE ETIOLOGIC ELEMENT OF DIABETIC NEUROPATHY
    ORDONEZ, G
    FERNANDEZ, A
    PEREZ, R
    SOTELO, J
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1994, 121 (02) : 163 - 166
  • [36] Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy - A randomized controled trial
    Apfel, SC
    Schwartz, S
    Adornato, BT
    Freeman, R
    Biton, V
    Rendell, M
    Vinik, A
    Giuliani, M
    Stevens, JC
    Barbano, R
    Dyck, PJ
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (17): : 2215 - 2221
  • [37] NERVE GROWTH FACTOR-INDUCED MUSCULAR MECHANICAL HYPERALGESIA AND SENSITIZATION TO MECHANICAL STIMULUS OF MUSCULAR C-FIBER AFFERENTS IN RATS
    Taguchi, Toru
    Cobar, Luis Fernando Queme
    Murase, Shiori
    Mizumura, Kazue
    JOURNAL OF PHYSIOLOGICAL SCIENCES, 2009, 59 : 379 - 379
  • [38] Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by Cisplatin: behavioral, structural and biochemical analysis
    Aloe, L
    Manni, L
    Properzi, F
    De Santis, S
    Fiore, M
    AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL, 2000, 86 (1-2): : 84 - 93
  • [39] GROWTH RESTORATION OF INSULIN-DEFICIENT DIABETIC RATS BY RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-I
    SCHEIWILLER, E
    GULER, HP
    MERRYWEATHER, J
    SCANDELLA, C
    MAERKI, W
    ZAPF, J
    FROESCH, ER
    NATURE, 1986, 323 (6084) : 169 - 171
  • [40] EFFECTS OF A-LIPOIC ACID COMBINED WITH METHYLCOBALAMIN ON SERUM SERUM HUMAN INSULIN-LIKE GROWTH FACTOR-1, HUMAN NERVE GROWTH FACTOR, AND MOTOR AND SENSORY NERVE CONDUCTION VELOCITY IN TYPE 2 DIABETIC PERIPHERAL NEUROPATHY
    Zhang, Li
    Li, Qin
    Kong, Dehuan
    ACTA MEDICA MEDITERRANEA, 2021, 37 (02): : 985 - 989